STERIS (STE) 10-Q 8 Feb 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Dec. 31, 2023	Feb. 05, 2024
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	0001757898
Document Type	10-Q
Document Period End Date	Dec. 31, 2023
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		98,814,035
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Local Phone Number	1 232 2000
City Area Code	353
Document Transition Report	false
Document Quarterly Report	true
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
Entity Shell Company	false
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE
Ordinary Shares
Entity Information [Line Items]
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 195,585	$ 208,357
Accounts receivable (net of allowances of $27,951 and $23,427, respectively)	964,022	928,315
Inventories, net	855,617	695,493
Prepaid expenses and other current assets	203,729	179,277
Total current assets	2,218,953	2,011,442
Property, plant, and equipment, net	1,844,484	1,705,512
Operating Lease, Right-of-Use Asset	195,413	191,741
Goodwill	4,111,683	3,879,219
Intangible Assets, Net (Excluding Goodwill)	2,987,287	2,955,780
Other assets	77,335	78,145
Total assets	11,435,155	10,821,839
Current liabilities:
Accounts payable	276,730	279,620
Accrued income taxes	24,880	43,804
Accrued payroll and other related liabilities	178,838	125,642
Capital Lease Obligations, Current	36,711	34,961
Short-term Debt	78,438	60,000
Accrued expenses and other	318,097	317,817
Total current liabilities	913,694	861,844
Long-term indebtedness	3,231,075	3,018,655
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	621,071	617,538
Capital Lease Obligations, Noncurrent	162,827	160,493
Other Liabilities, Noncurrent	78,389	76,137
Total liabilities	5,007,056	4,734,667
Commitments and contingencies (see Note 8)
Common shares, with $0.001 par value; 500,000 authorized; 98,808 shares issued; and 98,629 shares outstanding, respectively.	4,534,259	4,486,375
Retained earnings	2,133,766	1,911,533
Accumulated other comprehensive income	(252,629)	(320,710)
Total shareholders' equity	6,415,396	6,077,198
Noncontrolling interest	12,703	9,974
Total equity	6,428,099	6,087,172
Total liabilities and equity	$ 11,435,155	$ 10,821,839

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	500,000
Common Stock, Shares, Outstanding	98,808	98,629
Allowance for Doubtful Accounts Receivable, Current	$ 27,951	$ 23,427

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Revenues	$ 1,395,645	$ 1,215,994	$ 4,022,547	$ 3,573,002
Cost of revenues:
Total cost of revenues	793,052	694,497	2,252,964	2,001,372
Gross Profit	602,593	521,497	1,769,583	1,571,630
Operating expenses:
Selling, general, and administrative	360,518	305,141	1,100,227	962,962
Goodwill impairment loss	0	0	0	490,565
Research and development	25,913	25,514	78,459	75,193
Restructuring Costs	6	39	2	127
Total operating expenses	386,437	330,694	1,178,688	1,528,847
Income from operations	216,156	190,803	590,895	42,783
Non-operating expenses, net:
Interest expense	38,947	28,559	108,248	77,356
Interest income and miscellaneous expense	(2,080)	1,906	(4,710)	3,200
Total non-operating expenses, net	36,867	30,465	103,538	80,556
Income before income tax expense	179,289	160,338	487,357	(37,773)
Income tax expense	38,344	37,013	106,276	43,378
Net Income	140,945	123,325	381,081	(81,151)
Less: Net Income Attributable to Noncontrolling Interest	202	(503)	1,465	(956)
Net Income (Loss) Attributable to Shareholders	$ 140,743	$ 123,828	$ 379,616	$ (80,195)
Net income per common share [Abstract]
Basic	$ 1.42	$ 1.24	$ 3.84	$ (0.80)
Diluted	1.42	1.24	3.82	(0.80)
Cash dividends declared per common share outstanding	$ 0.52	$ 0.47	$ 1.51	$ 1.37
Product [Member]
Revenues:
Revenues	$ 804,756	$ 679,042	$ 2,280,950	$ 1,982,512
Cost of revenues:
Cost of Goods and Services Sold	439,005	374,729	1,223,415	1,058,663
Service [Member]
Revenues:
Revenues	590,889	536,952	1,741,597	1,590,490
Cost of revenues:
Cost of Goods and Services Sold	$ 354,047	$ 319,768	$ 1,029,549	$ 942,709

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Net Income	$ 140,945	$ 123,325	$ 381,081	$ (81,151)
Less: Net Income Attributable to Noncontrolling Interest	202	(503)	1,465	(956)
Net Income (Loss) Attributable to Shareholders	140,743	123,828	379,616	(80,195)
Other comprehensive (loss) income
Defined benefit plan changes (net of taxes $17, $8, $52, and $24, respectively)	58	27	175	83
Change in cumulative foreign current translation adjustment	134,048	233,958	67,906	(154,438)
Total other comprehensive (loss) income	134,106	233,985	68,081	(154,355)
Comprehensive income	$ 274,849	$ 357,813	$ 447,697	$ (234,550)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Amortization of pension and postretirement benefits plans costs, tax	$ 17	$ 8	$ 52	$ 24

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization	$ 430,806	$ 410,693
Deferred income taxes	(506)	(62,797)
Share-based compensation	47,588	29,857
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net	(971)	653
Loss on sale of businesses, net	0	3,939
Amortization of inventory fair value adjustments	4,722	2,477
Goodwill impairment loss	0	490,565
Other items	4,536	4,433
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net	(18,252)	(32,878)
Inventories, net	(123,349)	(130,434)
Other current assets	(22,841)	(46,116)
Accounts payable	(6,097)	18,819
Accruals and other, net	21,750	(66,912)
Net cash provided by operating activities	718,467	541,148
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(268,829)	(290,520)
Proceeds from the sale of property, plant, equipment, and intangibles	7,375	12,164
Proceeds from Divestiture of Businesses, Net of Cash Divested	9,458	6,624
Acquisition of businesses, net of cash acquired	(539,758)	(34,020)
Net cash used in investing activities	(791,754)	(305,752)
Financing activities:
Payments for Repurchase of Private Placement	0	91,000
Repayments of Secured Debt	(45,000)	(141,875)
Proceeds (Payments) under credit facilities, net	265,501	216,561
Acquisition related deferred or contingent consideration	(6,153)	(310)
Repurchases of ordinary shares	(11,440)	(153,952)
Cash dividends paid to ordinary shareholders	(149,173)	(136,898)
Payments to Noncontrolling Interests	(1,561)	(794)
Proceeds from issuance of equity to minority shareholders	2,883	0
Proceeds from (Payments for) Other Financing Activities	3,526	1,497
Net cash used in financing activities	58,583	(306,771)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	1,932	(17,574)
Decrease in cash and cash equivalents	(12,772)	(88,949)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	195,585	259,371
Net Income	$ 381,081	$ (81,151)

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 6,544,637
Stockholders' Equity Attributable to Parent			$ (209,808)	$ 1,999,244	$ 4,742,920
Noncontrolling interest		$ 12,281
Shares, Issued					100,067
Stockholders' Equity Attributable to Parent			(209,808)	1,999,244	$ 4,742,920
Stockholders' Equity Attributable to Noncontrolling Interest		12,281
Net Income (Loss) Attributable to Parent	(80,195)			(80,195)
Net Income (Loss) Attributable to Noncontrolling Interest	(956)	(956)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(81,151)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(154,355)		(154,355)
Treasury Stock, Shares, Acquired					850
Payments for Repurchase of Common Stock	153,952			11,379	$ 142,573
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					183
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	31,356				$ 31,356
Dividends, Common Stock, Cash	136,898			136,898
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Increase (Decrease) In Noncontrolling Interests, Other	$ (323)	(323)
Common Stock, Dividends, Per Share, Cash Paid	$ 1.37
Net Income (Loss) Attributable to Parent	$ (80,195)			(80,195)
Net Income (Loss) Attributable to Noncontrolling Interest	(956)	(956)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(81,151)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(154,355)		(154,355)
Treasury Stock, Shares, Acquired					(850)
Payments for Repurchase of Common Stock	(153,952)			(11,379)	$ (142,573)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					183
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	31,356				$ 31,356
Dividends, Common Stock, Cash	(136,898)			(136,898)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,813,447
Stockholders' Equity Attributable to Parent			(598,148)	1,695,087	$ 4,705,118
Noncontrolling interest		11,390
Shares, Issued					99,868
Stockholders' Equity Attributable to Parent			(598,148)	1,695,087	$ 4,705,118
Stockholders' Equity Attributable to Noncontrolling Interest		11,390
Net Income (Loss) Attributable to Parent	123,828			123,828
Net Income (Loss) Attributable to Noncontrolling Interest	(503)	(503)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	123,325
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	233,985		233,985
Treasury Stock, Shares, Acquired					493
Payments for Repurchase of Common Stock	84,030			1,226	$ 82,804
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					25
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	9,389				$ 9,389
Dividends, Common Stock, Cash	46,917			46,917
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Increase (Decrease) In Noncontrolling Interests, Other	$ 115	115
Common Stock, Dividends, Per Share, Cash Paid	$ 0.47
Net Income (Loss) Attributable to Parent	$ 123,828			123,828
Net Income (Loss) Attributable to Noncontrolling Interest	(503)	(503)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	123,325
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	233,985		233,985
Treasury Stock, Shares, Acquired					(493)
Payments for Repurchase of Common Stock	(84,030)			(1,226)	$ (82,804)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					25
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	9,389				$ 9,389
Dividends, Common Stock, Cash	(46,917)			(46,917)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,048,520
Stockholders' Equity Attributable to Parent			(364,163)	1,770,772	$ 4,631,703
Noncontrolling interest		10,208
Shares, Issued					99,400
Stockholders' Equity Attributable to Parent			(364,163)	1,770,772	$ 4,631,703
Stockholders' Equity Attributable to Noncontrolling Interest		10,208
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,087,172
Stockholders' Equity Attributable to Parent	6,077,198		(320,710)	1,911,533	$ 4,486,375
Noncontrolling interest	9,974	9,974
Shares, Issued					98,629
Stockholders' Equity Attributable to Parent	6,077,198		(320,710)	1,911,533	$ 4,486,375
Stockholders' Equity Attributable to Noncontrolling Interest	9,974	9,974
Net Income (Loss) Attributable to Parent	379,616			379,616
Net Income (Loss) Attributable to Noncontrolling Interest	1,465	1,465
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	381,081
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	68,081		68,081
Treasury Stock, Shares, Acquired					69
Payments for Repurchase of Common Stock	11,440			8,210	$ 3,230
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					248
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	51,114				$ 51,114
Dividends, Common Stock, Cash	149,173			149,173
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	1,561	1,561
Increase (Decrease) In Noncontrolling Interests, Other	(58)	(58)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	$ 2,883	2,883
Common Stock, Dividends, Per Share, Cash Paid	$ 1.51
Net Income (Loss) Attributable to Parent	$ 379,616			379,616
Net Income (Loss) Attributable to Noncontrolling Interest	1,465	1,465
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	381,081
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	68,081		68,081
Treasury Stock, Shares, Acquired					(69)
Payments for Repurchase of Common Stock	(11,440)			(8,210)	$ (3,230)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					248
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	51,114				$ 51,114
Dividends, Common Stock, Cash	(149,173)			(149,173)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	1,561	1,561
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,189,168
Stockholders' Equity Attributable to Parent			(386,735)	2,045,897	$ 4,518,911
Noncontrolling interest		11,095
Shares, Issued					98,789
Stockholders' Equity Attributable to Parent			(386,735)	2,045,897	$ 4,518,911
Stockholders' Equity Attributable to Noncontrolling Interest		11,095
Net Income (Loss) Attributable to Parent	140,743			140,743
Net Income (Loss) Attributable to Noncontrolling Interest	202	202
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	140,945
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	134,106		134,106
Treasury Stock, Shares, Acquired					12
Payments for Repurchase of Common Stock	2,228			1,497	$ 731
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					31
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	16,079				$ 16,079
Dividends, Common Stock, Cash	51,377			51,377
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	1,561	1,561
Increase (Decrease) In Noncontrolling Interests, Other	84	84
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	$ 2,883	2,883
Common Stock, Dividends, Per Share, Cash Paid	$ 0.52
Net Income (Loss) Attributable to Parent	$ 140,743			140,743
Net Income (Loss) Attributable to Noncontrolling Interest	202	202
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	140,945
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	134,106		134,106
Treasury Stock, Shares, Acquired					(12)
Payments for Repurchase of Common Stock	(2,228)			(1,497)	$ (731)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					31
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	16,079				$ 16,079
Dividends, Common Stock, Cash	(51,377)			(51,377)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	1,561	1,561
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,428,099
Stockholders' Equity Attributable to Parent	6,415,396		(252,629)	2,133,766	$ 4,534,259
Noncontrolling interest	12,703	12,703
Shares, Issued					98,808
Stockholders' Equity Attributable to Parent	6,415,396		$ (252,629)	$ 2,133,766	$ 4,534,259
Stockholders' Equity Attributable to Noncontrolling Interest	$ 12,703	$ 12,703

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies(Notes)	9 Months Ended
	Dec. 31, 2023
Notes To Financial Statements [Abstract]
Significant Accounting Policies	1. Nature of Operations and Summary of Significant Accounting Policies STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, endoscopy accessories, barrier products, and other products and services, including equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati on. We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies ("AST"), Life Sciences, and Dental. We describe our business segments in Note 9 titled "Business Segment Information." Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the Securities and Exchange Commission ("SEC") on May 26, 2023. The Consolidated Balance Sheet at March 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2023 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2024. Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2023, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 9 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our AST segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2024, $70,181 of the March 31, 2023 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2023, $76,861 of the March 31, 2022 deferred revenue balance was recorded as revenue. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the product has not passed to the Customer. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2023, the transaction price allocated to remaining performance obligations was approximately $1,555,119. We expect to recognize approximately 56% of the transaction price within one year and approximately 32% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2024 ASU 2022-04 "Liabilities - Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations." September 2022 The standard provides guidance to enhance the transparency of disclosures for entities that utilize supplier finance programs to include information about the key terms of the programs and present a rollforward of any obligations under the program where those obligations are presented in the balance sheet. Fiscal 2024 We adopted this standard in fiscal 2024 with no material impact to our consolidated financial statements. Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5 percent of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements in our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2023.

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	9 Months Ended
	Dec. 31, 2023
Business Acquisitions and Divestitures [Abstract]
Business Combination Disclosure	2. Business Acquisitions On August 2, 2023, we purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD (Becton, Dickinson and Company) (NYSE: BDX). The acquired assets from BD are being integrated into our Healthcare segment. The purchase price of the acquisition was $539,758. The acquisition also qualified for a tax benefit related to tax deductible goodwill, with a present value of approximately $60,000. The purchase price of the acquisition was financed with borrowings from our existing credit facility. For more information, refer to Note 5 titled, " Debt." The table below summarizes the preliminary allocation of the purchase price to the net assets acquired from BD based on fair values at the acquisition date. September 30, 2023 (As Previously Reported) Adjustments December 31, 2023 (1) Inventory 27,006 4,721 31,727 Property, plant, and equipment 6,755 1,109 7,864 Intangible assets 303,598 (598) 303,000 Goodwill 202,399 (5,232) 197,167 Total assets acquired 539,758 — 539,758 Net assets acquired $ 539,758 $ — $ 539,758 (1) Purchase price allocation is preliminary as of December 31, 2023, as valuations have not been finalized. During the first nine months of fiscal 2023, we completed several tuck-in acquisitions, which continued to expand our product and service offerings in the AST and Healthcare segments. Total aggregate consideration was approximately $40,720, including contingent deferred consideration of $6,700. Acquisition and integration expenses totaled $5,722 and $24,444 for the three and nine months ended December 31, 2023, respectively. Acquisition and integration expenses totaled $4,817 and $18,493 for the three and nine months ended December 31, 2022, respectively. The increase in acquisition and integration expenses for the three and nine months ended December 31, 2023 is primarily due to charges related to the acquisition of assets from BD and a fair value adjustment in the second quarter of fiscal 2024 related to a building held for sale from a previous acquisition. Acquisition and integration expenses are reported in the Selling, general and administrative expenses line of our Consolidated Statements of Income (Loss) and include, but are not limited to, investment banker, advisory, legal and other professional fees, and certain employee-related expenses.

Inventories, Net (Notes)

Inventories, Net (Notes)	9 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories, Net	3. Inventories, Net Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead . Inventories, net consisted of the following: December 31, March 31, Raw materials $ 303,691 $ 239,081 Work in process 117,882 97,756 Finished goods 492,005 404,238 Reserve for excess and obsolete inventory (57,961) (45,582) Inventories, net $ 855,617 $ 695,493

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	9 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	4. Property, Plant, and Equipment Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 97,381 $ 84,313 Buildings and leasehold improvements 756,059 691,933 Machinery and equipment 1,100,273 994,188 Information systems 260,639 247,873 Radioisotope 679,436 637,920 Construction in progress (1) 512,370 478,316 Total property, plant, and equipment 3,406,158 3,134,543 Less: accumulated depreciation and depletion (1,561,674) (1,429,031) Property, plant, and equipment, net $ 1,844,484 $ 1,705,512 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	9 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	5. Debt Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 37,813 $ 27,500 Delayed Draw Term Loan, current portion 40,625 32,500 Total short-term debt $ 78,438 $ 60,000 Long-term debt Private Placement Senior Notes $ 755,020 $ 750,302 Revolving Credit Facility 569,974 301,672 Deferred financing costs (18,607) (21,444) Term Loan 14,063 45,000 Delayed Draw Term Loan 560,625 593,125 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,231,075 $ 3,018,655 Total debt $ 3,309,513 $ 3,078,655 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	9 Months Ended
	Dec. 31, 2023
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	6. Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 68,083 $ 48,565 Accrued vacation/paid time off 16,798 11,080 Accrued bonuses 59,161 33,605 Accrued employee commissions 31,569 29,257 Other postretirement benefit obligations-current portion 1,121 1,121 Other employee benefit plans obligations-current portion 2,106 2,014 Total accrued payroll and other related liabilities $ 178,838 $ 125,642 Accrued expenses and other: Deferred revenues $ 90,373 $ 92,283 Service liabilities 80,620 72,033 Self-insured risk reserves-current portion 12,549 11,325 Accrued dealer commissions 36,386 31,096 Accrued warranty 14,951 13,683 Asset retirement obligation-current portion 535 543 Accrued interest 20,464 9,243 Other 62,219 87,611 Total accrued expenses and other $ 318,097 $ 317,817 Other liabilities: Self-insured risk reserves-long-term portion $ 22,171 $ 22,171 Other postretirement benefit obligations-long-term portion 5,778 6,070 Defined benefit pension plans obligations-long-term portion 3,214 2,876 Other employee benefit plans obligations-long-term portion 1,206 1,153 Accrued long-term income taxes 10,129 10,082 Asset retirement obligation-long-term portion 13,182 12,588 Other 22,709 21,197 Total other liabilities $ 78,389 $ 76,137

Income Tax Expense (Notes)

Income Tax Expense (Notes)	9 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax Expense	7. Income Taxes The effective income tax rates for the three month periods ended December 31, 2023 and 2022 were 21.4% and 23.1%, respectively. The fiscal 2024 effective tax rate for the three months ended December 31, 2023 decreased when compared to the prior year period, primarily due to favorable discrete items recognized during fiscal 2024. The effective income tax rates for the nine month periods ended December 31, 2023 and 2022 were 21.8% and (114.8)%, respectively. The fiscal 2024 effective tax rate for the nine months ended December 31, 2023 increased when compared to the prior year period, primarily due to the tax impact of the goodwill impairment loss recognized on the Dental segment during fiscal 2023. Income tax expense (benefit) is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2018 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2017. We remain subject to tax authority audits in various jurisdictions wherever we do business. In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 through 2017. An agreement was reached on final interest rates, which also impacts subsequent years through 2020. We estimate the total federal, state, and local tax impact of the settlement to be approximately $12,000, for the fiscal years 2016 through 2020, of which approximately $11,600 has been paid through December 31, 2023. In November 2023, we received two Notices of Deficiency from the IRS regarding the previously disclosed deemed dividend inclusions and associated withholding tax matter. The notices relate to the fiscal and calendar year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50,000. We are contesting the IRS’s assertions and have filed petitions with the U.S. Tax Court. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

Contingencies (Notes)

Contingencies (Notes)	9 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	8. Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or affect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims." From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Taxes” in this Quarterly Report on Form 10-Q.

Business Segment Information (N

Business Segment Information (Notes)	9 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Business Segment Information	9. Business Segment Information We operate and report our financial information in four reportable business segments: Healthcare, AST, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural products also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment is a third-party service provider for contract sterilization as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment. Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and nine months e nded December 31, 2023 and 2022 , revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. Three Customers collectively and consistently account for more than 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for appr oxi mately 47.5% and 44.5% o f our Dental segment revenues for the three and nine months ended December 31, 2023, respectively. These three Customers collectively accounted for approximately 47.2% and 43.8% of our Dental segment revenues for the three and nine months ended December 31, 2022, respectively. A dditional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023. Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Revenues: Healthcare $ 916,227 $ 769,144 $ 2,605,157 $ 2,200,483 AST 234,931 222,014 703,083 675,283 Life Sciences 146,566 121,273 411,074 379,248 Dental 97,921 103,563 303,233 317,988 Total revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002 Operating income (loss): Healthcare $ 223,898 $ 175,399 $ 626,134 $ 497,233 AST 105,156 103,539 325,529 323,238 Life Sciences 56,738 45,249 156,863 149,173 Dental 18,292 20,337 64,847 67,992 Corporate (81,359) (53,873) (261,265) (196,872) Total operating income $ 322,725 $ 290,651 $ 912,108 $ 840,764 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,850 $ 93,941 $ 286,786 $ 281,727 Acquisition and integration related charges (2) 5,722 4,817 24,444 18,493 Tax restructuring costs (3) 643 282 652 533 Gain on fair value adjustment of acquisition related contingent consideration (1) — — — (3,100) Net (gain) loss on divestiture of businesses (1) — (838) — 3,939 Amortization of inventory and property "step up" to fair value (1) 6,348 1,608 9,329 5,697 Restructuring charges (4) 6 38 2 127 Goodwill impairment loss (5) — — — 490,565 Total income from operations $ 216,156 $ 190,803 $ 590,895 $ 42,783 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures" included in our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023. (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to our Annual R eport on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023. (5) For more information regarding our goodwill impairment loss, see Note 17 to our consolidated financial statements titled, "Goodwill and Intangible Assets." Additional information regarding our fiscal 2024 and fiscal 2023 revenue is disclosed in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Healthcare: Capital equipment $ 266,838 $ 227,226 $ 759,842 $ 618,844 Consumables 329,435 259,810 915,741 757,892 Service 319,954 282,108 929,574 823,747 Total Healthcare Revenues $ 916,227 $ 769,144 $ 2,605,157 $ 2,200,483 AST: Capital equipment $ 5,241 $ 3,679 $ 7,869 $ 14,783 Service 229,690 218,335 695,214 660,500 Total AST Revenues $ 234,931 $ 222,014 $ 703,083 $ 675,283 Life Sciences: Capital equipment $ 44,836 $ 28,581 $ 111,265 $ 99,095 Consumables 60,072 55,610 181,179 172,587 Service 41,658 37,082 118,630 107,566 Total Life Sciences Revenues $ 146,566 $ 121,273 $ 411,074 $ 379,248 Dental Revenues $ 97,921 $ 103,563 $ 303,233 $ 317,988 Total Revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002 Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Revenues: Ireland $ 19,651 $ 17,959 $ 60,175 $ 53,130 United States 1,025,458 883,390 2,948,878 2,589,472 Other locations 350,536 314,645 1,013,494 930,400 Total Revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	9 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	10. Shares and Preferred Shares Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2023 2022 2023 2022 Weighted average shares outstanding—basic 98,802 99,716 98,765 99,922 Dilutive effect of share equivalents (1) 552 450 568 — Weighted average shares outstanding and share equivalents—diluted 99,354 100,166 99,333 99,922 (1) The dilutive effect of share equivalents is excluded from the calculation of diluted earnings per share for the nine months ended December 31, 2022 due to our net loss for that period. Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2023 2022 2023 2022 Number of share options 654 797 649 577 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Equity

Equity	9 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Treasury Stock	11. Repurchases of Ordinary Shares On May 3, 2023 our Board of Directors terminated the previous share repurchase program and authorized a new share repurchase program for the purchase of up to $500,000 (net of taxes, fees and commissions). This share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. During the first nine months of fiscal 2024, we had no share repurchase activity pursuant to authorizations under the share repurchase program. During the first nine months of fiscal 2023, we repurchased 775,320 of our ordinary shares for the aggregate amount of $148,306 (net of fees and commissions) pursuant to the authorizations under the share repurchase program. During the first nine months of fiscal 2024, we obtained 69,276 of our ordinary shares in the aggregate amount of $11,440 in connection with share-based compensation award programs. During the first nine months of fiscal 2023, we obtained 74,897 of our ordinary shares in the aggregate amount of $13,060 in connection with share-based compensation award programs.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	9 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	12. Share-Based Compensation We maintain a long-term ince ntive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a three or four year period or vest in equal tranches for each year of employment after the grant date. As of December 31, 2023, 2,368,027 ordinary shares remained available for grant under the long-term incentive plan. The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods, which may be impacted by retirement eligibility, in our Consolidated Statements of Income (Loss). The expense is classified as Cost of revenues or Selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted average assumptions were used for options granted during the first nine months of fiscal 2024 and 2023: Fiscal 2024 Fiscal 2023 Risk-free interest rate 3.59 % 2.44 % Expected life of options 6.0 years 5.9 years Expected dividend yield of stock 1.08 % 0.80 % Expected volatility of stock 27.92 % 24.49 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.22% and 2.54% was applied in fiscal 2024 and 2023, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2023 1,749,729 $ 154.60 Granted 253,946 220.24 Exercised (53,881) 60.54 Forfeited (3,415) 199.26 Outstanding at December 31, 2023 1,946,379 $ 165.69 6.1 years $ 112,785 Exercisable at December 31, 2023 1,343,419 $ 139.95 5.1 years $ 109,367 We estimate that 591,310 of the non-vested stock options outstanding at December 31, 2023 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $219.85 closing price of our ordinary shares on December 31, 2023 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes, and the value changes daily based on the daily changes in the fair market value of our ordinary shares. The total intrinsic value of stock options exercised during the first nine months of fiscal 2024 and fiscal 2023 was $8,350 and $4,638, respectively. Net cash proceeds from the exercise of stock options were $3,526 and $1,497 for the first nine months of fiscal 2024 and fiscal 2023, respectively. The weighted average grant date fair value of stock option grants was $54.60 and $50.72 for the first nine months of fiscal 2024 and fiscal 2023, respectively. A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2023 450,793 28,542 $ 186.60 Granted 173,074 18,344 201.48 Vested (146,912) (15,408) 163.81 Forfeited (13,714) (1,419) 194.71 Non-vested at December 31, 2023 463,241 30,059 $ 199.57 Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units at the time of grant that vested during the first nine months of fiscal 2024 was $26,487. As of December 31, 2023, there was a total of $68,670 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 1.8 years. Cantel Share Based Compensation Plan In connection with the acquisition of Cantel, outstanding, non-vested Cantel restricted share units were replaced with STERIS restricted share units. As of December 31, 2023, there was a total of $16 in unrecognized compensation cost related to non-vested STERIS restricted shar e units awarded to replace Cantel restricted share units. We expect to recognize the remaining cost by the fourth quarter of fiscal 2024. A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted Average Non-vested at March 31, 2023 15,670 $ 191.18 Vested (14,358) 191.18 Forfeited (762) 191.18 Non-vested at December 31, 2023 550 $ 191.18

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	9 Months Ended
	Dec. 31, 2023
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	13. Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first nine months of fiscal 2024 were as follows: Warranties Balance at March 31, 2023 $ 13,683 Warranties issued during the period 12,519 Settlements made during the period (11,251) Balance at December 31, 2023 $ 14,951

Deritvatives and Hedging (Notes

Deritvatives and Hedging (Notes)	9 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	14. Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including intercompany transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our Cost of revenues. During the third quarter of fiscal 2024, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar-denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature in fiscal 2024. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income (Loss). At December 31, 2023, we held net foreign currency forward contracts to buy 42.0 million British pounds sterling; and to sell 49.9 million Mexican pesos, 24.0 million Australian dollars, and 18.1 million euros. At December 31, 2023, we held commodity swap contracts to buy 188.3 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2023 March 31, 2023 December 31, 2023 March 31, 2023 Prepaid & other $ 742 $ 378 $ — $ — Accrued expenses and other $ — $ — $ 1,701 $ 2,054 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income (Loss): Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Foreign currency forward contracts Selling, general and administrative $ (292) $ 952 $ 1,226 $ 5,581 Commodity swap contracts Cost of revenues $ (316) $ 1,189 $ (1,708) $ (1,994)

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	9 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures	15. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2023 and March 31, 2023: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 195,585 $ 208,357 $ 195,585 $ 208,357 $ — $ — $ — $ — Forward and swap contracts (1) 742 378 — — 742 378 — — Equity investments (2) 8,099 7,069 8,099 7,069 — — — — Other investments 2,919 2,066 2,919 2,066 — — — — Liabilities: Forward and swap contracts (1) $ 1,701 $ 2,054 $ — $ — $ 1,701 $ 2,054 $ — $ — Deferred compensation plans (2) 1,082 1,022 1,082 1,022 — — — — Debt (3) 3,309,513 3,078,655 — — 3,039,581 2,754,218 — — Contingent consideration obligations (4) 10,801 15,678 — — — — 10,801 15,678 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous (income) expense" line of the Consolidated Statements of Income (Loss). During the third quarter and first nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. During the third quarter and first nine months of fiscal 2023, we recorded (losses) gains of $(342) and $1,385,respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2023 are summarized as follows: Contingent Consideration Balance at March 31, 2023 $ 15,678 Additions 1,087 Payments (5,947) Currency translation adjustments (17) Balance at December 31, 2023 $ 10,801

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Dec. 31, 2023
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	16. Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2023 and 2022 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 129 $ 12 $ (386,864) $ (320,722) $ (386,735) $ (320,710) Other Comprehensive Income (Loss) before reclassifications 408 1,160 134,048 67,906 134,456 69,066 Amounts reclassified from Accumulated Other Comprehensive Loss (350) (985) — — (350) (985) Net current-period Other Comprehensive Income (Loss) 58 175 134,048 67,906 134,106 68,081 Balance at December 31, 2023 $ 187 $ 187 $ (252,816) $ (252,816) $ (252,629) $ (252,629) (1) The amortization (gain) of defined benefit plan costs is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income (Loss). (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,332 $ 1,276 $ (599,480) $ (211,084) $ (598,148) $ (209,808) Other Comprehensive Income (Loss) before reclassifications 138 431 233,958 (154,438) 234,096 (154,007) Amounts reclassified from Accumulated Other Comprehensive Loss (111) (348) — — (111) (348) Net current-period Other Comprehensive Income (Loss) 27 83 233,958 (154,438) 233,985 (154,355) Balance at December 31, 2022 $ 1,359 $ 1,359 $ (365,522) $ (365,522) $ (364,163) $ (364,163) 1) The amortization (gain) of defined benefit plan costs is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income (Loss). (2)

Intangible Assets, Goodwill and

Intangible Assets, Goodwill and Other	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	17. Goodwill and Intangible Assets Changes to the carrying amount of goodwill for the nine months ended December 31, 2023 and 2022 are as follows: Healthcare Segment Life Sciences Segment AST Segment Dental Segment Total Balance at March 31, 2023 $ 2,301,273 $ 181,812 $ 1,396,134 $ — $ 3,879,219 Goodwill acquired 202,399 — — — 202,399 Measurement period adjustments to acquired goodwill (1) (7,805) — — — (7,805) Foreign currency translation adjustments 12,244 2,135 23,491 — 37,870 Balance at December 31, 2023 $ 2,508,111 $ 183,947 $ 1,419,625 $ — $ 4,111,683 Healthcare Segment Life Sciences Segment AST Segment Dental Segment Total Balance at March 31, 2022 $ 2,326,830 $ 179,288 $ 1,432,858 $ 465,367 $ 4,404,343 Goodwill acquired 10,753 — — — 10,753 Measurement period adjustments to acquired goodwill (1) (21,624) 3,147 — 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments (18,157) (1,073) (56,655) (15,367) (91,252) Balance at December 31, 2022 $ 2,295,444 $ 181,362 $ 1,376,203 $ — $ 3,853,009 1) Measurement period adjustments represent adjustments to the purchase price allocations for recent acquisitions whose allocations had been considered preliminary. See Note 2, titled "Business Acquisitions," for additional information regarding our recent business acquisitions. We evaluate the recoverability of recorded goodwill and indefinite-lived intangible assets annually during the third fiscal quarter, or when indicators of potential impairment exist. Our goodwill is assessed at the reporting unit level which is equivalent to the Company's reportable operating segments. As of the period ended December 31, 2023, there were no indicators that impairment of goodwill or indefinite-lived intangible assets was more likely than not. In the prior year period, we recorded a goodwill impairment charge of $490,565 related to our Dental segment. For more information regarding the goodwill impairment loss, refer to our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023. Identifiable intangible assets are reviewed for impairment when events and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We conduct this review on an ongoing basis, and, if impairment exists, we record the loss in the Consolidated Statements of Income during that period. When we evaluate these assets for impairment, we make certain judgments and estimates, including interpreting current economic indicators and market valuations, evaluating our strategic plans with regards to operations, historical and anticipated performance of operations, and other factors. It is possible that unfavorable developments related to these factors in the near term could result in an impairment loss relative to intangible assets. Such an impairment loss may be material to our results of operations in the period recorded.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 140,743	$ 123,828	$ 379,616	$ (80,195)

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2023 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2024.
Revenue	Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2023, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 9 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our AST segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2024, $70,181 of the March 31, 2023 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2023, $76,861 of the March 31, 2022 deferred revenue balance was recorded as revenue. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the product has not passed to the Customer. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services.

Accounting Policies (Tables)

Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
New Accounting Pronouncement, Early Adoption	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2024 ASU 2022-04 "Liabilities - Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations." September 2022 The standard provides guidance to enhance the transparency of disclosures for entities that utilize supplier finance programs to include information about the key terms of the programs and present a rollforward of any obligations under the program where those obligations are presented in the balance sheet. Fiscal 2024 We adopted this standard in fiscal 2024 with no material impact to our consolidated financial statements. Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5 percent of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)	9 Months Ended
	Dec. 31, 2023
Business Acquisitions and Divestitures [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The table below summarizes the preliminary allocation of the purchase price to the net assets acquired from BD based on fair values at the acquisition date. September 30, 2023 (As Previously Reported) Adjustments December 31, 2023 (1) Inventory 27,006 4,721 31,727 Property, plant, and equipment 6,755 1,109 7,864 Intangible assets 303,598 (598) 303,000 Goodwill 202,399 (5,232) 197,167 Total assets acquired 539,758 — 539,758 Net assets acquired $ 539,758 $ — $ 539,758 (1) Purchase price allocation is preliminary as of December 31, 2023, as valuations have not been finalized.

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	9 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	December 31, March 31, Raw materials $ 303,691 $ 239,081 Work in process 117,882 97,756 Finished goods 492,005 404,238 Reserve for excess and obsolete inventory (57,961) (45,582) Inventories, net $ 855,617 $ 695,493

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 97,381 $ 84,313 Buildings and leasehold improvements 756,059 691,933 Machinery and equipment 1,100,273 994,188 Information systems 260,639 247,873 Radioisotope 679,436 637,920 Construction in progress (1) 512,370 478,316 Total property, plant, and equipment 3,406,158 3,134,543 Less: accumulated depreciation and depletion (1,561,674) (1,429,031) Property, plant, and equipment, net $ 1,844,484 $ 1,705,512 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	9 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 37,813 $ 27,500 Delayed Draw Term Loan, current portion 40,625 32,500 Total short-term debt $ 78,438 $ 60,000 Long-term debt Private Placement Senior Notes $ 755,020 $ 750,302 Revolving Credit Facility 569,974 301,672 Deferred financing costs (18,607) (21,444) Term Loan 14,063 45,000 Delayed Draw Term Loan 560,625 593,125 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,231,075 $ 3,018,655 Total debt $ 3,309,513 $ 3,078,655

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	9 Months Ended
	Dec. 31, 2023
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	6. Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 68,083 $ 48,565 Accrued vacation/paid time off 16,798 11,080 Accrued bonuses 59,161 33,605 Accrued employee commissions 31,569 29,257 Other postretirement benefit obligations-current portion 1,121 1,121 Other employee benefit plans obligations-current portion 2,106 2,014 Total accrued payroll and other related liabilities $ 178,838 $ 125,642 Accrued expenses and other: Deferred revenues $ 90,373 $ 92,283 Service liabilities 80,620 72,033 Self-insured risk reserves-current portion 12,549 11,325 Accrued dealer commissions 36,386 31,096 Accrued warranty 14,951 13,683 Asset retirement obligation-current portion 535 543 Accrued interest 20,464 9,243 Other 62,219 87,611 Total accrued expenses and other $ 318,097 $ 317,817 Other liabilities: Self-insured risk reserves-long-term portion $ 22,171 $ 22,171 Other postretirement benefit obligations-long-term portion 5,778 6,070 Defined benefit pension plans obligations-long-term portion 3,214 2,876 Other employee benefit plans obligations-long-term portion 1,206 1,153 Accrued long-term income taxes 10,129 10,082 Asset retirement obligation-long-term portion 13,182 12,588 Other 22,709 21,197 Total other liabilities $ 78,389 $ 76,137
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 68,083 $ 48,565 Accrued vacation/paid time off 16,798 11,080 Accrued bonuses 59,161 33,605 Accrued employee commissions 31,569 29,257 Other postretirement benefit obligations-current portion 1,121 1,121 Other employee benefit plans obligations-current portion 2,106 2,014 Total accrued payroll and other related liabilities $ 178,838 $ 125,642 Accrued expenses and other: Deferred revenues $ 90,373 $ 92,283 Service liabilities 80,620 72,033 Self-insured risk reserves-current portion 12,549 11,325 Accrued dealer commissions 36,386 31,096 Accrued warranty 14,951 13,683 Asset retirement obligation-current portion 535 543 Accrued interest 20,464 9,243 Other 62,219 87,611 Total accrued expenses and other $ 318,097 $ 317,817 Other liabilities: Self-insured risk reserves-long-term portion $ 22,171 $ 22,171 Other postretirement benefit obligations-long-term portion 5,778 6,070 Defined benefit pension plans obligations-long-term portion 3,214 2,876 Other employee benefit plans obligations-long-term portion 1,206 1,153 Accrued long-term income taxes 10,129 10,082 Asset retirement obligation-long-term portion 13,182 12,588 Other 22,709 21,197 Total other liabilities $ 78,389 $ 76,137

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	9 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Revenues: Healthcare $ 916,227 $ 769,144 $ 2,605,157 $ 2,200,483 AST 234,931 222,014 703,083 675,283 Life Sciences 146,566 121,273 411,074 379,248 Dental 97,921 103,563 303,233 317,988 Total revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002 Operating income (loss): Healthcare $ 223,898 $ 175,399 $ 626,134 $ 497,233 AST 105,156 103,539 325,529 323,238 Life Sciences 56,738 45,249 156,863 149,173 Dental 18,292 20,337 64,847 67,992 Corporate (81,359) (53,873) (261,265) (196,872) Total operating income $ 322,725 $ 290,651 $ 912,108 $ 840,764 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,850 $ 93,941 $ 286,786 $ 281,727 Acquisition and integration related charges (2) 5,722 4,817 24,444 18,493 Tax restructuring costs (3) 643 282 652 533 Gain on fair value adjustment of acquisition related contingent consideration (1) — — — (3,100) Net (gain) loss on divestiture of businesses (1) — (838) — 3,939 Amortization of inventory and property "step up" to fair value (1) 6,348 1,608 9,329 5,697 Restructuring charges (4) 6 38 2 127 Goodwill impairment loss (5) — — — 490,565 Total income from operations $ 216,156 $ 190,803 $ 590,895 $ 42,783
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Healthcare: Capital equipment $ 266,838 $ 227,226 $ 759,842 $ 618,844 Consumables 329,435 259,810 915,741 757,892 Service 319,954 282,108 929,574 823,747 Total Healthcare Revenues $ 916,227 $ 769,144 $ 2,605,157 $ 2,200,483 AST: Capital equipment $ 5,241 $ 3,679 $ 7,869 $ 14,783 Service 229,690 218,335 695,214 660,500 Total AST Revenues $ 234,931 $ 222,014 $ 703,083 $ 675,283 Life Sciences: Capital equipment $ 44,836 $ 28,581 $ 111,265 $ 99,095 Consumables 60,072 55,610 181,179 172,587 Service 41,658 37,082 118,630 107,566 Total Life Sciences Revenues $ 146,566 $ 121,273 $ 411,074 $ 379,248 Dental Revenues $ 97,921 $ 103,563 $ 303,233 $ 317,988 Total Revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Revenues: Ireland $ 19,651 $ 17,959 $ 60,175 $ 53,130 United States 1,025,458 883,390 2,948,878 2,589,472 Other locations 350,536 314,645 1,013,494 930,400 Total Revenues $ 1,395,645 $ 1,215,994 $ 4,022,547 $ 3,573,002

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	9 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2023 2022 2023 2022 Weighted average shares outstanding—basic 98,802 99,716 98,765 99,922 Dilutive effect of share equivalents (1) 552 450 568 — Weighted average shares outstanding and share equivalents—diluted 99,354 100,166 99,333 99,922 (1)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2023 2022 2023 2022 Number of share options 654 797 649 577

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted average assumptions were used for options granted during the first nine months of fiscal 2024 and 2023: Fiscal 2024 Fiscal 2023 Risk-free interest rate 3.59 % 2.44 % Expected life of options 6.0 years 5.9 years Expected dividend yield of stock 1.08 % 0.80 % Expected volatility of stock 27.92 % 24.49 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2023 1,749,729 $ 154.60 Granted 253,946 220.24 Exercised (53,881) 60.54 Forfeited (3,415) 199.26 Outstanding at December 31, 2023 1,946,379 $ 165.69 6.1 years $ 112,785 Exercisable at December 31, 2023 1,343,419 $ 139.95 5.1 years $ 109,367
Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest	A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2023 450,793 28,542 $ 186.60 Granted 173,074 18,344 201.48 Vested (146,912) (15,408) 163.81 Forfeited (13,714) (1,419) 194.71 Non-vested at December 31, 2023 463,241 30,059 $ 199.57
Share-based Payment Arrangement, Activity	A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted Average Non-vested at March 31, 2023 15,670 $ 191.18 Vested (14,358) 191.18 Forfeited (762) 191.18 Non-vested at December 31, 2023 550 $ 191.18

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	9 Months Ended
	Dec. 31, 2023
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first nine months of fiscal 2024 were as follows: Warranties Balance at March 31, 2023 $ 13,683 Warranties issued during the period 12,519 Settlements made during the period (11,251) Balance at December 31, 2023 $ 14,951

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	9 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2023 March 31, 2023 December 31, 2023 March 31, 2023 Prepaid & other $ 742 $ 378 $ — $ — Accrued expenses and other $ — $ — $ 1,701 $ 2,054
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income (Loss): Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Foreign currency forward contracts Selling, general and administrative $ (292) $ 952 $ 1,226 $ 5,581 Commodity swap contracts Cost of revenues $ (316) $ 1,189 $ (1,708) $ (1,994)

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Option, Disclosures	The following table shows the fair value of our financial assets and liabilities at December 31, 2023 and March 31, 2023: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 195,585 $ 208,357 $ 195,585 $ 208,357 $ — $ — $ — $ — Forward and swap contracts (1) 742 378 — — 742 378 — — Equity investments (2) 8,099 7,069 8,099 7,069 — — — — Other investments 2,919 2,066 2,919 2,066 — — — — Liabilities: Forward and swap contracts (1) $ 1,701 $ 2,054 $ — $ — $ 1,701 $ 2,054 $ — $ — Deferred compensation plans (2) 1,082 1,022 1,082 1,022 — — — — Debt (3) 3,309,513 3,078,655 — — 3,039,581 2,754,218 — — Contingent consideration obligations (4) 10,801 15,678 — — — — 10,801 15,678 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous (income) expense" line of the Consolidated Statements of Income (Loss). During the third quarter and first nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. During the third quarter and first nine months of fiscal 2023, we recorded (losses) gains of $(342) and $1,385,respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2023 are summarized as follows: Contingent Consideration Balance at March 31, 2023 $ 15,678 Additions 1,087 Payments (5,947) Currency translation adjustments (17) Balance at December 31, 2023 $ 10,801

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Dec. 31, 2023
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2023 and 2022 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 129 $ 12 $ (386,864) $ (320,722) $ (386,735) $ (320,710) Other Comprehensive Income (Loss) before reclassifications 408 1,160 134,048 67,906 134,456 69,066 Amounts reclassified from Accumulated Other Comprehensive Loss (350) (985) — — (350) (985) Net current-period Other Comprehensive Income (Loss) 58 175 134,048 67,906 134,106 68,081 Balance at December 31, 2023 $ 187 $ 187 $ (252,816) $ (252,816) $ (252,629) $ (252,629) (1) The amortization (gain) of defined benefit plan costs is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income (Loss). (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,332 $ 1,276 $ (599,480) $ (211,084) $ (598,148) $ (209,808) Other Comprehensive Income (Loss) before reclassifications 138 431 233,958 (154,438) 234,096 (154,007) Amounts reclassified from Accumulated Other Comprehensive Loss (111) (348) — — (111) (348) Net current-period Other Comprehensive Income (Loss) 27 83 233,958 (154,438) 233,985 (154,355) Balance at December 31, 2022 $ 1,359 $ 1,359 $ (365,522) $ (365,522) $ (364,163) $ (364,163) 1) The amortization (gain) of defined benefit plan costs is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income (Loss). (2)

Intangible Assets, Goodwill a_2

Intangible Assets, Goodwill and Other (Tables)	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes to the carrying amount of goodwill for the nine months ended December 31, 2023 and 2022 are as follows: Healthcare Segment Life Sciences Segment AST Segment Dental Segment Total Balance at March 31, 2023 $ 2,301,273 $ 181,812 $ 1,396,134 $ — $ 3,879,219 Goodwill acquired 202,399 — — — 202,399 Measurement period adjustments to acquired goodwill (1) (7,805) — — — (7,805) Foreign currency translation adjustments 12,244 2,135 23,491 — 37,870 Balance at December 31, 2023 $ 2,508,111 $ 183,947 $ 1,419,625 $ — $ 4,111,683 Healthcare Segment Life Sciences Segment AST Segment Dental Segment Total Balance at March 31, 2022 $ 2,326,830 $ 179,288 $ 1,432,858 $ 465,367 $ 4,404,343 Goodwill acquired 10,753 — — — 10,753 Measurement period adjustments to acquired goodwill (1) (21,624) 3,147 — 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments (18,157) (1,073) (56,655) (15,367) (91,252) Balance at December 31, 2022 $ 2,295,444 $ 181,362 $ 1,376,203 $ — $ 3,853,009

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Amount	$ 1,555,119
Deferred Revenue, Revenue Recognized	$ 70,181	$ 76,861
Expected recognition within the next year [Member]
Revenue, Remaining Performance Obligation, Percentage	56%
Expected recognition beyond the next year [Member] [Member]
Revenue, Remaining Performance Obligation, Percentage	32%

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Fiscal Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition [Line Items]
Contingent consideration	$ 10,801		$ 10,801			$ 15,678
Deferred consideration		$ 6,700		$ 6,700
Gain (Loss) on Disposition of Business	0	838	0	(3,939)
Business Combination, Acquisition Related Costs	5,722	4,817	24,444	18,493
Goodwill	4,111,683	$ 3,853,009	4,111,683	3,853,009		$ 3,879,219	$ 4,404,343
Payments to Acquire Businesses, Net of Cash Acquired			539,758	34,020
Goodwill, Purchase Accounting Adjustments			(7,805)	22,088
Asset Acquisition, Price of Acquisition Net of Tax Benefit, Expected			60,000
BD Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			539,758
Other FY 23 Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 40,720
BD Acquisition
Business Acquisition [Line Items]
Inventory	31,727		31,727		$ 27,006
Property, plant, and equipment	7,864		7,864		6,755
Intangible assets	303,000		303,000		303,598
Goodwill	197,167		197,167		202,399
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	539,758		539,758		539,758
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	539,758		$ 539,758		$ 539,758
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory	4,721
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment	1,109
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles	(598)
Goodwill, Purchase Accounting Adjustments	(5,232)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets	0
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets Acquired	$ 0

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Raw materials	$ 303,691	$ 239,081
Work in process	117,882	97,756
Finished goods	492,005	404,238
Reserve for excess and obsolete inventory	(57,961)	(45,582)
Inventories, net	$ 855,617	$ 695,493

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2023	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment		Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 97,381 $ 84,313 Buildings and leasehold improvements 756,059 691,933 Machinery and equipment 1,100,273 994,188 Information systems 260,639 247,873 Radioisotope 679,436 637,920 Construction in progress (1) 512,370 478,316 Total property, plant, and equipment 3,406,158 3,134,543 Less: accumulated depreciation and depletion (1,561,674) (1,429,031) Property, plant, and equipment, net $ 1,844,484 $ 1,705,512 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
Property, Plant and Equipment [Line Items]
Land and land improvements	[1]	$ 97,381	$ 84,313
Buildings and leasehold improvements		756,059	691,933
Machinery and equipment		1,100,273	994,188
Capitalized Computer Hardware/Software, Gross		260,639	247,873
Radioisotope		679,436	637,920
Construction in progress	[1]	512,370	478,316
Total property, plant, and equipment		3,406,158	3,134,543
Less: accumulated depreciation and depletion		(1,561,674)	(1,429,031)
Property, plant, and equipment, net		$ 1,844,484	$ 1,705,512
[1] Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 37,813 $ 27,500 Delayed Draw Term Loan, current portion 40,625 32,500 Total short-term debt $ 78,438 $ 60,000 Long-term debt Private Placement Senior Notes $ 755,020 $ 750,302 Revolving Credit Facility 569,974 301,672 Deferred financing costs (18,607) (21,444) Term Loan 14,063 45,000 Delayed Draw Term Loan 560,625 593,125 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,231,075 $ 3,018,655 Total debt $ 3,309,513 $ 3,078,655
Debt Instrument [Line Items]
Deferred financing costs	$ (18,607)	$ (21,444)
Credit Agreement	569,974	301,672
Total long term debt	3,231,075	3,018,655
Debt, Long-term and Short-term, Combined Amount	3,309,513	3,078,655
Short-term Debt	78,438	60,000
Term loan, current portion	37,813	27,500
Term Loan	14,063	45,000
Delayed Draw Term Loan	560,625	593,125
Delayed draw term loan, current portion	40,625	32,500
Senior Notes
Debt Instrument [Line Items]
Senior Notes, Noncurrent	1,350,000	1,350,000
Private Placement
Debt Instrument [Line Items]
Senior Notes, Noncurrent	$ 755,020	$ 750,302

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Accrued payroll and other related liabilities:
Compensation and related items	$ 68,083	$ 48,565
Accrued vacation/paid time off	16,798	11,080
Accrued bonuses	59,161	33,605
Accrued employee commissions	31,569	29,257
Other postretirement benefit obligations-current portion	1,121	1,121
Other employee benefit plans obligations-current portion	2,106	2,014
Employee-related Liabilities, Current	178,838	125,642
Accrued expenses and other:
Deferred revenues	90,373	92,283
Service liabilities	80,620	72,033
Self-insured risk reserves-current portion	12,549	11,325
Accrued dealer commissions	36,386	31,096
Accrued warranty	14,951	13,683
Asset retirement obligation-current portion	535	543
Accrued interest	20,464	9,243
Other	62,219	87,611
Accrued Liabilities, Current	318,097	317,817
Other liabilities:
Self-insured risk reserves-long-term portion	22,171	22,171
Other postretirement benefit obligations-long-term portion	5,778	6,070
Defined benefit pension plans obligations-long-term portion	3,214	2,876
Other employee benefit plans obligations-long-term portion	1,206	1,153
Accrued long-term income taxes	10,129	10,082
Asset retirement obligation-long-term portion	13,182	12,588
Long-term liabilities, other	22,709	21,197
Other Liabilities, Noncurrent	$ 78,389	$ 76,137

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	21.40%	23.10%	21.80%	(114.80%)
Uncertain Tax Liability Resulting From IRS Notice	$ 50,000		$ 50,000
Income Tax Examination, Estimate of Possible Loss			12,000
Income tax examination, amount of loss paid			$ 11,600

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 1,395,645	$ 1,215,994	$ 4,022,547	$ 3,573,002
Segment operating income	216,156	190,803	590,895	42,783
Restructuring Charges	6	38	2	127
Goodwill impairment loss	0	0	0	490,565
Amortization of acquired intangible assets	93,850	93,941	286,786	281,727
Business Combination, Acquisition Related Costs	5,722	4,817	24,444	18,493
loss (gain) on fair value contingent consideration adjustments	0	0	0	(3,100)
Impact of TCJA	643	282	652	533
Net loss on divestiture of businesses	0	(838)	0	3,939
Amortization of inventory and property step-up to fair value	6,348	1,608	9,329	5,697
Assets	11,435,155		11,435,155		$ 10,821,839
Property, Plant and Equipment, Net	1,844,484		1,844,484		$ 1,705,512
Life Sciences
Segment Reporting Information [Line Items]
Revenues	146,566	121,273	411,074	379,248
Segment operating income	56,738	45,249	156,863	149,173
Corporate
Segment Reporting Information [Line Items]
Segment operating income	(81,359)	(53,873)	(261,265)	(196,872)
Segment operating income
Segment Reporting Information [Line Items]
Segment operating income	322,725	290,651	912,108	840,764
Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	916,227	769,144	2,605,157	2,200,483
Segment operating income	223,898	175,399	626,134	497,233
Dental
Segment Reporting Information [Line Items]
Revenues	97,921	103,563	303,233	317,988
Segment operating income	$ 18,292	$ 20,337	$ 64,847	$ 67,992
Dental | Revenue Benchmark | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	47.50%	47.20%	44.50%	43.80%
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues	$ 234,931	$ 222,014	$ 703,083	$ 675,283
Segment operating income	105,156	103,539	325,529	323,238
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues	350,536	314,645	1,013,494	930,400
UNITED STATES
Segment Reporting Information [Line Items]
Revenues	1,025,458	883,390	2,948,878	2,589,472
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues	19,651	17,959	60,175	53,130
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	60,072	55,610	181,179	172,587
Consumable revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	329,435	259,810	915,741	757,892
Sales Revenue, Services, Net [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	41,658	37,082	118,630	107,566
Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	319,954	282,108	929,574	823,747
Sales Revenue, Services, Net [Member] | Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues	229,690	218,335	695,214	660,500
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	44,836	28,581	111,265	99,095
Capital equipment revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	266,838	227,226	759,842	618,844
Capital equipment revenues [Member] | Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues	$ 5,241	$ 3,679	$ 7,869	$ 14,783

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 shares	Dec. 31, 2023 EUR (€) shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	98,802,000	99,716,000	98,765,000	99,922,000
Dilutive effect of share equivalents	552,000	450,000	568,000	0
Weighted average shares outstanding and share equivalents - diluted	99,354,000	100,166,000	99,333,000	99,922,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized					50,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Deferred Ordinary Shares					25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	654,000	797,000	649,000	577,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €					€ 1

Shares and Preferred Shares Pre

Shares and Preferred Shares Preferred Shares (Details)	Dec. 31, 2023 $ / shares
Class of Stock [Line Items]
Preferred shares, par value	$ 0.001

Repurchases of Shares (Details)

Repurchases of Shares (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	May 03, 2023
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized			$ 500,000
Shares repurchased during period, number		775,320
Aggregate value of shares repurchased pursuant to authorization		$ 148,306
Shares obtained in connection with share based compensation award programs	69,276	74,897
Payments for shares obtained in connection with share based compensation programs	$ 11,440	$ 13,060

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	2,368,027
Weighted-average assumptions used for options granted:
Risk-free interest rate	3.59%	2.44%
Expected life of options	6 years	5 years 10 months 24 days
Exptected dividend yield of stock	1.08%	0.80%
Expected volatility of stock	27.92%	24.49%
Estimated forfeiture rate	2.22%	2.54%
Summary of share option activity:
Outstanding at the beginning of the period	1,749,729
Granted	253,946
Exercised	(53,881)
Forfeited	(3,415)
Outstanding at the end of the period	1,946,379
Exercisable at the end of the period	1,343,419
Weighted average exercise price:
Outstanding at March 31, 2023	$ 154.60
Granted	220.24
Exercised	60.54
Forfeited	199.26
Outstanding at December 31, 2023	165.69
Exercisable at December 31, 2023	$ 139.95
Average Remaining Contractual Term, Outstanding at the end of the period	6 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding at the end of the period	$ 112,785
Average Remaining Contractual Term, Exercisable at the end of the period	5 years 1 month 6 days
Aggregate Intrinsic Value, Exercisable at the end of the period	$ 109,367
Non-vested stock options outstanding expected to vest	591,310
Ordinary shares, closing price	$ 219.85
Total intrinsic value of stock options exercised	$ 8,350	$ 4,638
Net cash proceeds from the exercise of stock options	$ 3,526	$ 1,497
Weighted average grant date fair value of stock option grants, per share	$ 54.60	$ 50.72
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 68,670
Weighted Average Period For Total Compensation Expense Not Yet Recognized	1 year 9 months 18 days
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	450,793
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 186.60
Number of Restricted Shares, Granted	173,074
Weighted-Average Grant Date Fair Value, Granted	$ 201.48
Number of Restricted Shares, Vested	(146,912)
Weighted-Average Grant Date Fair Value, Vested	$ 163.81
Number of Restricted Shares, Canceled	(13,714)
Weighted-Average Grant Date Fair Value, Canceled	$ 194.71
Number of Restricted Shares, Non-vested at End of Period	463,241
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 199.57
Fair Value, Share-based Payment Awards, Other than Options	$ 26,487
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	28,542
Number of Restricted Shares, Granted	18,344
Number of Restricted Shares, Vested	(15,408)
Number of Restricted Shares, Canceled	(1,419)
Number of Restricted Shares, Non-vested at End of Period	30,059
RSUs Cantel
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	15,670
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 191.18
Number of Restricted Shares, Vested	(14,358)
Weighted-Average Grant Date Fair Value, Vested	$ 191.18
Number of Restricted Shares, Canceled	(762)
Weighted-Average Grant Date Fair Value, Canceled	$ 191.18
Number of Restricted Shares, Non-vested at End of Period	550
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 191.18
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 16

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2023 USD ($)
Product Warranty Liability [Line Items]
Balance, Beginning of the Period	$ 13,683
Warranties issued during the period	12,519
Settlement made during the period	(11,251)
Balance, End of the Period	$ 14,951

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, £ in Millions, $ in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) lb	Dec. 31, 2022 USD ($)	Dec. 31, 2023 GBP (£)	Dec. 31, 2023 MXN ($)	Dec. 31, 2023 AUD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)
Prepaid & Other
Derivative [Line Items]
Asset derivatives									$ 742	$ 378
Liability derivatives									0	0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives									0	0
Liability derivatives									$ 1,701	$ 2,054
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative [Line Items]
Amount of gain (loss) recognized in income	$ (292)	$ 952	$ 1,226	$ 5,581
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb			188,300
Commodity swap contracts | Cost of Sales [Member]
Derivative [Line Items]
Amount of gain (loss) recognized in income	$ (316)	$ 1,189	$ (1,708)	$ (1,994)
Mexican peso | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount						$ 49.9
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount | €								€ 18.1
British pounds sterling | Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives | £					£ 42
Australia, Dollars | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount							$ 24

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (292)	$ 952	$ 1,226	$ 5,581
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (316)	$ 1,189	$ (1,708)	$ (1,994)

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Reported Value Measurement [Member]
Assets:
Cash and cash equivalents		$ 195,585		$ 195,585		$ 208,357
Forward and swap contracts	[1]	742		742		378
Equity Securities, FV-NI	[2]	8,099		8,099		7,069
Investments		2,919		2,919		2,066
Liabilities:
Deferred compensation plans	[2]	1,082		1,082		1,022
Long term debt	[3]	3,309,513		3,309,513		3,078,655
Contingent consideration obligations		10,801		10,801		15,678
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	1,701		1,701		2,054
Debt and Equity Securities, Gain (Loss)		(881)	$ 342	(1,019)	$ (1,385)
Contingent consideration obligations		10,801		10,801		15,678
Level 1
Assets:
Cash and cash equivalents		195,585		195,585		208,357
Forward and swap contracts		0		0		0
Equity Securities, FV-NI	[2]	8,099		8,099		7,069
Investments		2,919		2,919		2,066
Liabilities:
Deferred compensation plans	[2]	1,082		1,082		1,022
Long term debt	[3]	0		0		0
Contingent consideration obligations		0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure		0		0		0
Level 2
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts	[1]	742		742		378
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Deferred compensation plans		0		0		0
Long term debt	[3]	3,039,581		3,039,581		2,754,218
Contingent consideration obligations		0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	1,701		1,701		2,054
Level 3
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts		0		0		0
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Deferred compensation plans		0		0		0
Long term debt	[3]	0		0		0
Contingent consideration obligations	[4]	10,801		10,801		15,678
Foreign Currency Contracts, Liability, Fair Value Disclosure		$ 0		$ 0		$ 0
[1] The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous (income) expense" line of the Consolidated Statements of Income (Loss). During the third quarter and first nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. During the third quarter and first nine months of fiscal 2023, we recorded (losses) gains of $(342) and $1,385,respectively, related to these investments. We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s.

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2023	Mar. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration		$ 10,801	$ 15,678
Additions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		1,087
Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(5,947)
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(17)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	[1]	10,801	15,678
Fair value		$ 0	$ 0
[1]Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates

Fair Value Measurements Availab

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Equity Securities, FV-NI, Gain (Loss)	$ 881	$ (342)	$ 1,019	$ 1,385

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended				9 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2023		Dec. 31, 2022		Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (252,629)		$ (364,163)		$ (252,629)		$ (364,163)		$ (386,735)	$ (320,710)	$ (598,148)	$ (209,808)
Other Comprehensive Income (Loss), Net of Tax		134,456		234,096		69,066		(154,007)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(350)		(111)	[1]	(985)		(348)
Total other comprehensive (loss) income		134,106		233,985		68,081		(154,355)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		187		1,359		187		1,359		129	12	1,332	1,276
Other Comprehensive Income (Loss), Net of Tax		408		138		1,160		431
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	(350)		(111)		(985)		(348)
Total other comprehensive (loss) income		58		27		175		83
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(252,816)		(365,522)		(252,816)		(365,522)		$ (386,864)	$ (320,722)	$ (599,480)	$ (211,084)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		134,048		233,958		67,906		(154,438)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	[1]	0		0	[1]	0	[1]
Total other comprehensive (loss) income		$ 134,048		$ 233,958		$ 67,906		$ (154,438)
[1]The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.[2]The amortization (gain) of defined benefit plan costs is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income (Loss).

Intangible Assets, Goodwill a_3

Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Goodwill [Line Items]
Goodwill	$ 4,111,683	$ 3,853,009	$ 4,111,683	$ 3,853,009	$ 3,879,219	$ 4,404,343
Goodwill, Acquired During Period			202,399	10,753
Goodwill impairment loss	0	0	0	490,565
Goodwill, Written off Related to Sale of Business Unit				(2,358)
Goodwill, Foreign Currency Translation Gain (Loss)			37,870	(91,252)
Goodwill, Purchase Accounting Adjustments			(7,805)	22,088
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,419,625	1,376,203	1,419,625	1,376,203	1,396,134	1,432,858
Goodwill, Acquired During Period			0	0
Goodwill impairment loss				0
Goodwill, Written off Related to Sale of Business Unit				0
Goodwill, Foreign Currency Translation Gain (Loss)			23,491	(56,655)
Goodwill, Purchase Accounting Adjustments			0	0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill	183,947	181,362	183,947	181,362	181,812	179,288
Goodwill, Acquired During Period			0	0
Goodwill impairment loss				0
Goodwill, Written off Related to Sale of Business Unit				0
Goodwill, Foreign Currency Translation Gain (Loss)			2,135	(1,073)
Goodwill, Purchase Accounting Adjustments			0	3,147
Dental
Goodwill [Line Items]
Goodwill	0	0	0	0	0	465,367
Goodwill, Acquired During Period			0	0
Goodwill impairment loss				490,565
Goodwill, Written off Related to Sale of Business Unit				0
Goodwill, Foreign Currency Translation Gain (Loss)			0	(15,367)
Goodwill, Purchase Accounting Adjustments			0	40,565
Healthcare
Goodwill [Line Items]
Goodwill	$ 2,508,111	$ 2,295,444	2,508,111	2,295,444	$ 2,301,273	$ 2,326,830
Goodwill, Acquired During Period			202,399	10,753
Goodwill impairment loss				0
Goodwill, Written off Related to Sale of Business Unit				(2,358)
Goodwill, Foreign Currency Translation Gain (Loss)			12,244	(18,157)
Goodwill, Purchase Accounting Adjustments			$ (7,805)	$ (21,624)

Uncategorized Items - ste-20231

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 208,357,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 348,320,000